Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new drug last month and ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...